Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Beyond Pfizer/AstraZeneca, Plenty Of Fish In The Sea

Executive Summary

Deals continue outside of the focus on Pfizer/AstraZeneca, with Novartis expanding its ophthalmology portfolio; Viking licensing five metabolic disease candidates from Ligand; BioAlliance and Topotarget moving closer to a merger creating a new orphan oncology firm to be called Onxeo; Ventrus and Assembly planning their own merger to focus on hepatitis B; and Daiichi Sankyo and Sanford-Burnham signing an R&D collaboration on novel cardiovascular and metabolic disease targets.

You may also be interested in...

Viking Explores Metabolic Disorders With Drugs Licensed From Ligand

The start-up is launching with a focus on metabolic and endocrine disorders through a deal with Ligand that will flesh out its pipeline and give it a major shareholder.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts